Boston completes enrolment in Phase ll trial of PAZ320
A total of 24 adult patients with type 2 diabetes, on insulin or oral agents, with a body mass index of 25-40kg/m² and with an A1C of less
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.